| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 9.9 | 12.7 |
| Gross profit | -0.1 | 1.0 |
| Profit before tax | -0.9 | 0.2 |
| Net income | -0.7 | 0.1 |
| EPS (diluted, $ a share) | $-0.02 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -21.9% |
|---|---|
| Gross margin | -1.1% |
| Operating margin | -9.7% |
10-Q filed with the SEC, OTC: INBP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Integrated Biopharma Inc: key numbers
- Share price
- $0.1800Close, Nov 16
- Market cap
- $5.59M
- Shares outstanding
- 31.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Integrated Biopharma Inc
All →Integrated Biopharma Financial Results
Integrated BioPharma reported a 22% revenue decline to $9.9 million for the quarter ended September 30, 2026, resulting in a net loss of $0.7 million. The company noted significant customer concentration, with its two largest contract manufacturing clients accounting for 88% of total revenue.
- Term
- Q1 2027
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”
Riva Sheppard and Christina Kay, Co-Chief Executive Officers
Integrated Biopharma Financial Results
Integrated BioPharma reported financial results for its fiscal year ended June 30, 2026, showing a 19.3% revenue decrease to $43.9 million. The company swung to a net loss of $2.8 million ($0.09 per share) compared to a net income of $0.8 million in the prior fiscal year, driven by lower sales and an operating loss of $2.7 million.
- Term
- FY2026
“Our revenue decreased by approximately 19% in our fiscal year ended June 30, 2026 from the fiscal year ended June 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 84% of total revenue in our fiscal years ended June 30, 2026 and 2025, respectively.”
Riva Sheppard and Christina Kay, Co-Chief Executive Officers